Summary
A research-focused comparison of Selank and Semax — two anxiolytic and cognitive-enhancing peptides developed in Russia, examining their mechanisms, BDNF effects, anxiety research, and key differences.
Two Peptides, One Research Institution
Selank and Semax share more than a research category. Both were developed at the same institution — the Institute of Molecular Genetics of the Russian Academy of Sciences — and both emerged from decades of Soviet and post-Soviet neurological research that remained largely unknown to Western researchers until the 2000s.
They are frequently discussed together because their target audience overlaps: researchers and clinicians interested in anxiety, stress response, cognitive performance, and neuroprotection. Yet they are mechanistically distinct, act through different primary pathways, and produce different profiles in the published literature.
This article examines what makes them similar, what makes them different, and what the research actually shows.
What Is Selank?
Selank is a synthetic heptapeptide (seven amino acids) developed as a stable analogue of tuftsin — an endogenous tetrapeptide derived from the Fc region of immunoglobulin G.
Tuftsin naturally modulates immune function and has been observed to influence anxiety and stress behaviour in animal models. Selank was engineered to preserve and amplify these neurological properties while improving stability and half-life through structural modification.
Its sequence is: Thr-Lys-Pro-Arg-Pro-Gly-Pro.
Primary Mechanisms
GABA-A receptor modulation: Selank has been shown to modulate GABA-A receptor activity — the same receptor system targeted by benzodiazepines — though through a different binding mechanism. This is considered central to its anxiolytic profile.
Serotonin and dopamine system interaction: Research has observed Selank influencing the metabolism of serotonin and dopamine in brain regions associated with anxiety and mood regulation, including the hippocampus and frontal cortex.
BDNF upregulation: Brain-Derived Neurotrophic Factor (BDNF) is a protein essential for neuron survival, synaptic plasticity, and learning. Selank has been observed to increase BDNF expression in animal models — an effect associated with both anxiolytic and cognitive outcomes.
Enkephalin metabolism: Selank appears to inhibit enzymes that degrade enkephalins — endogenous opioid peptides involved in pain and mood regulation — potentially prolonging their activity.
Anxiety Research
Selank's most consistent finding in the literature is its anxiolytic effect.
In rodent models using standard anxiety tests (elevated plus maze, open field, light-dark box), Selank reliably reduces anxiety-related behaviour at doses that do not impair motor function — a distinction from benzodiazepines, which produce sedation alongside anxiolysis.
Human clinical data exists: a study published in Bulletin of Experimental Biology and Medicine examined Selank in patients with generalised anxiety disorder. Researchers reported reduced anxiety scores on validated rating scales, with onset within the first week of treatment and no reported withdrawal effects or rebound anxiety upon discontinuation — a profile notably different from benzodiazepine drugs.
The absence of dependence potential in the published data is considered one of Selank's most clinically interesting properties.
Cognitive and Nootropic Research
Beyond anxiety, Selank has been studied in learning and memory models.
Findings include:
- Improved performance in spatial learning tasks in rodent models
- Enhanced consolidation of memory traces following training
- Protection of cognitive function under conditions of stress or hypoxia
- Neuroprotective effects in models of neuronal damage
These findings are attributed to the combination of BDNF upregulation and neurotransmitter system modulation.
What Is Semax?
Semax is a synthetic heptapeptide derived from ACTH(4-7) — a fragment of adrenocorticotropic hormone — with a Pro-Gly-Pro sequence added to enhance stability.
Its sequence is: Met-Glu-His-Phe-Pro-Gly-Pro.
Unlike Selank, Semax has no anxiolytic origin. It was developed as a cognitive enhancer and neuroprotective agent, with early research focused on stroke recovery and cerebrovascular conditions. It has been used in Russian clinical settings since the 1980s.
Primary Mechanisms
BDNF and NGF upregulation: Semax is one of the most potent peptide inducers of BDNF and Nerve Growth Factor (NGF) reported in the literature. NGF supports the survival and function of cholinergic neurons — the same population implicated in Alzheimer's disease and age-related cognitive decline.
Dopaminergic and serotonergic activity: Semax modulates dopamine and serotonin systems, contributing to its stimulant-like cognitive effects and mood elevation.
Melanocortin receptor activity: As an ACTH fragment, Semax acts on melanocortin receptors. MC4R in particular is involved in cognitive function, stress response, and attention regulation.
Anti-inflammatory neuroprotection: Research has observed Semax reducing neuroinflammation markers in models of ischemic brain injury — a finding that underlies its clinical use in stroke rehabilitation contexts.
Cognitive Research
Semax's cognitive enhancement profile is more pronounced and stimulant-adjacent compared to Selank.
Published findings include:
- Significant improvements in attention and working memory in healthy human subjects under stress conditions
- Enhanced learning speed in rodent models across multiple paradigms
- Improvement in cognitive performance markers in patients with mild cognitive impairment
- Protection of cognitive function following experimental ischemia
Semax is registered as a pharmaceutical drug in Russia for cerebrovascular insufficiency and stroke recovery — one of the few nootropic peptides with formal regulatory status anywhere in the world.
Neuroprotective Research
The neuroprotective literature for Semax is substantial.
Key findings:
- Reduced infarct volume in rodent stroke models
- Preservation of neuronal populations following ischemic injury
- Reduction in oxidative stress markers in brain tissue
- Enhancement of nerve regeneration processes
These neuroprotective findings have driven interest in Semax beyond cognitive enhancement into the broader neurology research space.
Direct Comparison
Mechanism Overview
| Property | Selank | Semax |
|---|---|---|
| Origin | Tuftsin analogue | ACTH(4-7) fragment |
| Primary target | GABA-A, serotonin, enkephalins | Melanocortin receptors, BDNF/NGF |
| BDNF effect | Moderate increase | Strong increase |
| NGF effect | Limited data | Strong increase |
| Anxiolytic activity | Primary effect | Secondary / indirect |
| Cognitive enhancement | Moderate | Strong |
| Stimulant quality | None | Mild-moderate |
| Sedation risk | None reported | None reported |
| Neuroprotection data | Moderate | Extensive |
| Clinical use history | Anxiety, stress | Stroke, cognitive decline |
| Regulatory status (Russia) | Registered | Registered |
Effect Profile Comparison
For anxiety and stress: Selank is the stronger candidate in the published literature. Its GABA-A modulation and clean anxiolytic profile without sedation or dependence risk places it in a different category from both Semax and standard pharmacological anxiolytics.
For cognitive performance and focus: Semax is more pronounced. Its BDNF/NGF effects, melanocortin activity, and stimulant-adjacent profile make it the choice in research examining attention, learning speed, and working memory under load.
For neuroprotection and recovery: Semax has the more extensive evidence base, driven by its clinical history in cerebrovascular conditions.
For mood: Both compounds influence serotonin and dopamine systems. Selank tends to produce a calmer, more stable mood effect; Semax produces something closer to motivated clarity. Both have been reported to improve mood in clinical observations.
Can They Be Used Together?
Selank and Semax are frequently discussed in combination in research contexts, based on the hypothesis that their complementary mechanisms — GABA modulation (Selank) and BDNF/melanocortin activation (Semax) — could produce additive or synergistic effects on both anxiety reduction and cognitive enhancement simultaneously.
No published controlled study has examined the combination directly. Researchers studying both compounds have noted the theoretical rationale, and the compounds do not share receptor targets in ways that would create obvious interference.
Delivery: Why Nasal Administration?
Both Selank and Semax have been studied and clinically used primarily via intranasal administration in Russia.
The nasal route is particularly well-suited to these peptides for a specific reason: the olfactory nerve provides a direct anatomical pathway from the nasal mucosa to the brain, bypassing the blood-brain barrier. This olfactory transport mechanism — demonstrated for several small peptides — allows peptides that would otherwise struggle to cross the BBB to reach central nervous system targets efficiently.
Research has confirmed that intranasally administered Semax reaches the brain via this olfactory pathway in rodent models. The same route is presumed to contribute to Selank's CNS activity, though the precise transport mechanisms for each compound continue to be studied.
This is why both compounds are most commonly formulated as nasal sprays for research applications, rather than subcutaneous injections — their CNS targets are reached more directly via the olfactory-trigeminal pathway than through systemic circulation.
Safety Profile
Both compounds have extensive use histories in Russian clinical settings, spanning several decades.
Selank: No significant adverse effects reported in published literature. No dependence, tolerance, or withdrawal has been documented. The GABA-A modulatory mechanism appears fundamentally different from benzodiazepines in terms of its dependence pharmacology.
Semax: Similarly well tolerated across its long clinical history. No significant adverse events reported at studied doses. Its stimulant-adjacent profile may be unsuitable for evening use in some research contexts.
Neither compound is approved outside Russia as a pharmaceutical. Both are available as research compounds.
Frequently Asked Questions
What is the main difference between Selank and Semax?
Selank primarily acts as an anxiolytic through GABA-A modulation and serotonin system interaction, with moderate cognitive enhancement. Semax primarily acts as a cognitive enhancer and neuroprotective agent through BDNF/NGF upregulation and melanocortin receptor activity, with stimulant-adjacent focus effects.
Which is better for anxiety?
The published literature consistently shows Selank as the stronger anxiolytic. Its GABA-A modulation and documented efficacy in generalised anxiety disorder research, without sedation or dependence, makes it the primary choice in this research context.
Which is better for focus and productivity?
Semax's BDNF and melanocortin receptor effects make it the stronger choice in cognitive performance research. Its profile is closer to a clean stimulant than an anxiolytic.
Why are they taken as nasal sprays?
The olfactory pathway provides direct access to the brain from the nasal mucosa, bypassing the blood-brain barrier. Research has confirmed this pathway for Semax, and both compounds are formulated as nasal sprays for CNS-targeted delivery.
Can Selank and Semax be combined?
No published controlled study has examined the combination. Mechanistically, their targets are complementary rather than overlapping, and the theoretical rationale for combination exists — but direct evidence is absent.
Are Selank and Semax legal?
Both are registered pharmaceutical drugs in Russia. Outside Russia, their legal status varies by jurisdiction. As research compounds, they are supplied for laboratory use only.
References
Semenova TP et al. Selank affects the behaviour of anxious rats and the metabolism of serotonin in their brain. Eksperimental'naia i Klinicheskaia Farmakologiia. 2010.
Zozulia AA et al. Efficacy and possible mechanisms of the anxiolytic action of Selank. Bulletin of Experimental Biology and Medicine. 2001.
Grigoriev VV et al. Semax affects the expression of BDNF and its receptor in the hippocampus. Doklady Biological Sciences. 2006.
Davydova TV et al. Semax and Selank in the correction of cognitive impairment. Experimental Biology and Medicine. Published data.
Miasoedov NF et al. Study of Semax action on the processes of learning and memory in rats. Peptides. 1999.
Research Use Only Disclaimer
BioPepTech products are supplied strictly for research use only. They are not intended for human consumption and are not intended to diagnose, treat, cure, or prevent disease.